Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$26.04 -1.64%

-$0.38 today

Market cap
$1.81B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 1.02M

Average 0.71M

ZYME Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Zymeworks Inc.NASDAQ: ZYME

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables growth accelerates

Q3 FY2026 accounts payables of $55.07M rose 1548.2% year over year, ahead of the +357.1% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 22.3% of revenue in FY2025, up 3.5 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1548.2% holds above the trailing-twelve-month pace of +357.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$55.07M+1622.4% QoQ
Last fiscal yearDec 2025
-$23.65M-265.0% YoY
LTMSep 2026
$45.36M+357.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1548.2%——
1 year-265.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(23.65M) USD
Year-over-year change
-265.0%

Accounts Payables vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's LTM Sep 2026 accounts payables of $45.36M is the largest of the 11 companies compared; the peer median is $119.68K.
  • Its year-over-year change of +357.1% is the 2nd highest of 10, against a peer median of -91.2%.
  • Accounts payables amounts to 17.1% of revenue for ZYME, versus a peer median of 3.3%.
ZYME Competitors Peer median
Accounts Payables for ZYME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$45.36M +357.1%—17.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$13.63M -5.5%+52.3%12167.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$10.3M -925.0%—13.0%
XNCRXencor, Inc.LTM Jun 2026$6.13M -229.5%+0.3%5.8%
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M -48.2%-70.5%1.5%
IMNMImmunome, Inc.LTM Sep 2026$1.13M -147.6%+138.3%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.09M +164.9%+48.1%3.1%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$233K -91.2%-54.6%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$6.37K -100.5%—0.1%
CGENCompugen Ltd.LTM Dec 2025$0 ——0.0%
Peer median (excluding ZYME) $119.68K-91.2%+24.2%3.3%

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
Deferred Income Tax(953K)1.94M(757K)691K945K
Stock-Based Compensation10.76M4.02M8.1M17.79M28.03M
Change in Working Capital393K4.02M(25.55M)(30.95M)7.5M
Accounts Receivables(266K)(17.51M)13.92M(36.36M)51.2M
Inventory00000
Accounts Payables16.48M26.48M(44.77M)14.34M(23.65M)
Other Working Capital(15.82M)(4.96M)5.3M(8.93M)(20.05M)
Other Non-Cash Items(387K)(2.21M)1.27M13.93M532K
Operating Cash Flow(192.45M)144.11M(118.3M)(110.04M)(33.01M)
Capital Expenditures(13.29M)(13.13M)(4.08M)(3.07M)(1.52M)
Acquisitions (Net)00000
Purchases of Investments(35.08M)(40.72M)(553.25M)(283.74M)(196.06M)
Sales of Investments192.96M(40.72M)350.07M325.57M225.08M
Other Investing Activities(881K)40.72M(1.6M)(1.08M)0
Investing Cash Flow144.6M(53.85M)(207.25M)38.76M26.66M
Debt Repayment(17K)(14K)(21K)(14K)0
Common Stock Issued0107.53M76.1M023.32M
Common Stock Repurchased000(30.05M)(41.7M)
Dividends Paid00000
Other Financing Activities8.03M1.06M5.77M9.61M(181K)
Financing Cash Flow8.01M108.58M81.85M(20.45M)(18.56M)
Effect of Forex Changes(325K)203K354K286K(45K)
Net Change in Cash(40.17M)199.05M(243.36M)(91.45M)(24.95M)
Free Cash Flow(205.74M)130.98M(122.38M)(113.11M)(34.53M)

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$26.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.